Sentences with phrase «phase i trial targeting»

«Results in Phase I trial targeting cancer stem cells.»

Not exact matches

Cambridge, MA — March 30, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that it has enrolled and dosed the first patient in its Phase 1b clinical trial of light - activated AU - 011, an investigational, first - in - class targeted therapy in development for the treatment of ocular melanoma, a rare and life - threatening disease.

For example, an MDM2 - targeting drug shrank deep - tissue fat cell tumors in just one out of 20 patients in a phase I safety trial, published in 2012.

«The results of the phase III clinical trial show that a target fusion biopsy detects more clinically significant prostate cancer,» said Art Rastinehad, DO, principal investigator of the study and director of interventonal urologic oncology at North Shore - LIJ's Arthur Smith Institute for Urology, in New Hyde Park, NY.

Italy's National Institute of Health in Rome recently completed a phase II clinical trial of an experimental vaccine that targets the Tat protein.

And it launched its first two phase I trials without announcing what diseases they targeted — a decision Bancel attributes to fears that financial markets would prematurely pigeonhole the company into a particular field.

One successful compound, named Exel 647, that targets nonsmall - cell lung cancer in previously untreated patients is now in a phase 2 clinical trial.

The phase I and phase I / II trials aimed to measure the safety of adding HCQ to either chemotherapy, radiation therapy or targeted therapies, its effectiveness at inhibiting autophagy, and the potential clinical benefit of HCQ combination therapies.

Last week, Rib - X announced that it had raised US$ 18.7 million to help the company start phase III trials of an antibiotic that could target skin infections.

«People have been targeting telomerase as a potential cancer therapy for a long time,» he says, noting that anti-telomerase drugs are in phase II clinical trials against several cancers.

One phase I trial of an immune checkpoint blockade drug combined with two established targeted therapies yielded 40 - 50 percent response rates among patients with metastatic kidney cancer.

«We are delighted to receive this CIRM grant that will drive our translational research from the laboratory to the clinic,» Slamon said, «and allow us to test our targeted drug in a phase I clinical trial.»

The study is investigator led and has therefore focused on clinical need, targeting patients with progressive multiple sclerosis in whom most disability is incurred... The study also reports a predominant effect on neurodegenerative rather than inflammatory outcomes, suggesting a novel mechanism of action that might be suitable as combination treatment with immunomodulatory treatments... Further phase 3 studies to measure the effect of simvastatin on sustained disability, particularly in patients with non-relapsing secondary progressive and primary progressive multiple sclerosis, are clearly needed, but this trial represents a promising point from which to develop trials of progressive disease.»

A new drug that targets not only common cancer - causing genetic mutations in patients with non-small cell lung cancer (NSCLC), but also a form of the mutation that causes resistance to treatment, has shown promising results in patients in a phase I / II clinical trial.

In fact, the researchers point out that phase 1 clinical trials are already underway for compounds targeting this gene in other cancers, meaning that the time needed to apply a similar strategy to mucosal melanoma could be dramatically shorter than if they had to start from scratch.

«We demonstrated that quality can be accomplished across the sites, but consider a different approach to the design,» she said, explaining that rather than treating negative symptom patients as one homogenous target, priority should be given to exploring the usefulness of novel mechanisms in separate negative symptom domains to better define the target population and maximize the chance of success before launching large phase III trials.

ETC - 159 is presently in a Phase I clinical trial to target different cancers.

Results from a phase III trial with another antibody that targets β amyloid — solanezumab, developed by Eli Lilly — should be announced later this year.

After identifying three different types of resistance to a promising investigational lung cancer drug in a phase 1 trial, a team of researchers led by Dana - Farber Cancer Institute scientists say new targeted inhibitors and combinations are urgently needed to stay ahead of tumors» constant and varied molecular shape - shifting.

Dr James Larkin, a Consultant Medical Oncologist at The Royal Marsden, London, UK, told the 2015 European Cancer Congress [1], that results from the CheckMate 067 phase III clinical trial had already shown that the combination of the two drugs, which target two different pathways that regulate the immune system, improved the progression - free survival in patients with melanoma who had not received any other treatment.

A research team led by Christine Brown, Ph.D., and a clinical team headed by Behnam Badie, M.D., has received a $ 12.8 million grant from the CIRM to fund a phase 1 chimeric antigen receptor (CAR) T cell trial targeting an aggressive brain cancer called malignant glioma, which includes glioblastoma.

The targeted antibody bevacizumab (Avastin ®) is already approved for ovarian cancer patients, and a number of immune - based therapies are being investigated in early - phase clinical trials for patients with ovarian cancer.

Illustrating the tricky path current Alzheimer's research faces, the study was published literally hours after giant pharmaceutical company Merck announced the cancellation of a Phase 3 clinical trial surrounding a drug that targets the exact same enzyme.

My translational research interests involve clinical trials evaluating targeted biologic agents, particularly early phase trials with targeted antibodies.

NGF is in fact viewed as a viable target for AD clinical trials with one group investigating NGF ex vivo gene delivery in a Phase 1 trial with human patients aimed at stimulating cholinergic function and improving memory [123].

Genetic Analysis Guides Prostate Cancer Treatment Genetic analysis of Ken Tucker's prostate cancer revealed that he was eligible to participate in a new, targeted treatment available through a Phase I clinical trial.

It exhibited safety in animal studies, and preliminary evidence of both target engagement and clinical efficacy in its Phase I and Phase II trials.

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Prothena Corporation plc (NASDAQ: PRTA), announced today that they have entered into a worldwide collaboration to develop and commercialize antibodies that target alpha - synuclein, including PRX002... which is currently in preclinical development and is expected to enter Phase 1 clinical trials in patients with Parkinson's disease in 2014.

He conducts phase 1 and 2 clinical trials of novel targeted agents.

Our group has 3 major goals: Develop novel therapeutic approaches based on centrosomal clustering To further develop our first prototype inhibitors of centrosomal clustering preclinically and to establish a robust and specific high throughput small molecule screen Discover key events in myeloma pathogenesis To investigate the pivotal transition from the pre-malignant, asymptomatic to malignant, symptomatic stages of plasma cell dyscrasias in order to understand the pathophysiology and thereby identify novel targets Translate small molecule therapeutics from bench to clinical trials To evaluate novel agents in the preclinical setting and to initiate early phase clinical trials in hematologic malignancies with focus on multiple myeloma

Clinical Trials Research and Billing First in Human / Early Phase PET in Oncology Case - Based Dose Reduction in Pediatric Nuclear Medicine: Practical and Necessary Radioiodine Therapy for Hyperthyroidism: The State of the Art Spondylodiscitis: Role of Imaging for Diagnosis and Monitoring Treatment Response Current Status and Future Prospects: PET and SPECT Instrumentation Alternative Payment Models and Value - Based Health Care: Nuts and Bolts Maximal Tolerated Activity of Radioactive Iodine for Metastatic Thyroid Cancer Teaching Old Radiopharmaceuticals New Tricks Intraoperative Detection Devices and Probes Molecular Imaging of Lung Inflammation Standardization of Advanced PET / SPECT Data Acquisition and Analysis Thyroid Cancer Management: Novel Therapeutics and Management Options Targeting Radionuclide Therapy in Various Non-Malignant Arthritic Conditions Using Radiosynoviorthesis (RSO) Are You Prepared for a Radiation Accident?

Fortunately, there are a number of targeted drugs in phase III clinical trials.

In the next several years, when the laboratory process for recreating micro tumors is fast and reliable, Dr. Simeone expects to offer a Phase 1 clinical trial to design tailored single and combination therapies, as well as experimental agents targeting specific mutations.

Gladstone established the Assay Development and Drug Discovery Core to help scientists accelerate their research into target and drug - discovery phases and move their findings into clinical trials and potential therapies for disease.

And the company just filed an application to begin Phase I trials of its ALAS - 1 targeting treatment for hepatic porphyrias (a class of rare inherited disorders that are the result of deficiencies in some enzymes of the liver), according to the release.

The Center for Cancer Targeted Therapies (C2T2) integrates a phase I - Ib / early clinical trials program, a precision cancer medicine infrastructure with expertise on tumor tissue - based state - of - the - art molecular methods, and a core resource with novel non-invasive functional imaging methods.

Target lesion responses with PV - 10 in the phase II trial were consistently more robust in patients with stage III melanoma than in patients with stage IV disease; similarly, response duration was significantly longer in patients with stage III melanoma than in those with stage IV melanoma — 9.6 months vs 3.1 months (P <.001).

To further develop genetically directed early phase clinical trials — in part through Center for Cancer Targeted Therapeutics (C2T2), Early Cancer Therapeutics Consortium (ECTC), National Clinical Trials Network (NCTN) with Molecular Analysis for Therapy Choice (Mtrials — in part through Center for Cancer Targeted Therapeutics (C2T2), Early Cancer Therapeutics Consortium (ECTC), National Clinical Trials Network (NCTN) with Molecular Analysis for Therapy Choice (MTrials Network (NCTN) with Molecular Analysis for Therapy Choice (MATCH).

Although the genetic evidence strongly supports the targeting of γ - secretases (Szaruga et al, 2017; Voytyuk et al, 2017) to lower amyloid - β generation in the brain of patients, the severe side effects observed in phase 3 clinical trials have brought γ - secretase research almost to an end (Doody et al, 2013; De Strooper, 2014).

National Cancer Institute and ECOG - ACRIN announce the July 2015 opening of the NCI - MATCH / EAY131 trial, a multi-arm phase II precision medicine study that seeks to determine whether targeted therapies for people whose tumors have specific gene mutations will be effective regardless of cancer type.

Co-author of the Bisgrove Phase I clinical trial published in fall 2009: A Pilot Study Using Molecular Profiling of Patients» Tumors to Find Potential Targets and Select Treatments for their Refractory Cancers.